
    
      The primary purpose of this study is to evaluate the efficacy of lurasidone 20 mg/day in
      subjects with an acute exacerbation of schizophrenia. This study will also evaluate the
      efficacy and safety of lurasidone 80 mg/day and160 mg/day versus placebo in subjects who are
      early non-responders (operationally defined per protocol) to lurasidone 80 mg/day.
    
  